Tirzepatide
Tirzepatide (Mounjaro/Zepbound)
A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and obesity. Demonstrates significant weight loss and metabolic improvements in large clinical trials.
How Tirzepatide Works
Tirzepatide is a dual GLP-1/GIP receptor agonist that uniquely activates both incretin pathways. The GLP-1 component enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and acts on hypothalamic appetite centers to reduce hunger. The GIP component complements this by enhancing insulin sensitivity, improving lipid metabolism, and potentially increasing energy expenditure. The dual mechanism produces superior glycemic control and weight loss compared to GLP-1 single agonists, with the SURMOUNT trials demonstrating up to 22.5% body weight reduction.
📊 Evidence by Outcome
FDA-approved. SURMOUNT trials showed up to 22.5% weight loss at highest dose.
15 studies • Consistency: High • Effect: Very Large
Superior HbA1c reduction compared to other diabetes medications.
12 studies • Consistency: High • Effect: Large
Key Research
Peer-Reviewed Evidence • 3 Citations
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)
Frias JP et al.•N Engl J Med•2021•PMID: 34170647
Key Finding: Tirzepatide demonstrated superior HbA1c reduction and weight loss compared to semaglutide across all doses in head-to-head trial.
View on PubMedTirzepatide for treatment of adults with overweight or obesity (SURMOUNT-1)
Jastreboff AM et al.•N Engl J Med•2022•PMID: 35658024
Key Finding: Tirzepatide achieved 22.5% weight loss at highest dose — transformative results for obesity pharmacotherapy.
View on PubMedDual GIP/GLP-1 receptor agonism: An emerging approach for treating type 2 diabetes and obesity
Nauck MA, D'Alessio DA•Diabetes Obes Metab•2020•PMID: 32267090
Key Finding: Dual incretin agonism provides additive metabolic benefits through complementary pathways, offering superior efficacy to single-target drugs.
View on PubMedCitations sourced from PubMed, Cochrane Library, and peer-reviewed journals. Study findings are summarized for accessibility. Always consult the original publication for full methodology and results.
Side Effects & Safety
Interactions & Contraindications
Drug Interactions
- •Insulin and sulfonylureas — significant hypoglycemia risk (dose reduction required)
- •Oral medications — delayed gastric emptying reduces absorption rate; particularly important for narrow therapeutic index drugs
- •Oral contraceptives — switch to non-oral contraception or use backup method during dose escalation
- •Warfarin — monitor INR during initiation and dose changes
Supplement Interactions
- •Oral supplements may have altered absorption timing
- •Electrolyte supplementation may be needed with significant GI losses
- •Protein supplementation recommended to counter lean mass loss
Food & Timing
- •Eat smaller, more frequent meals to manage nausea
- •Avoid high-fat, greasy, and fried foods
- •High-protein diet essential (aim for 1.2-1.6g protein per kg body weight)
- •Stay well hydrated — minimum 2-3 liters of water daily
- •Avoid carbonated beverages if experiencing bloating
Who Should Avoid
- •Personal or family history of medullary thyroid carcinoma (MTC)
- •Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- •History of pancreatitis
- •Pregnancy and breastfeeding (discontinue at least 2 months before planned conception due to long half-life)
- •Type 1 diabetes
- •Severe gastrointestinal disease (gastroparesis)
- •Known hypersensitivity to tirzepatide
📋 Protocol Snapshot
Protocols are for informational purposes only. Always consult a qualified healthcare provider before starting any treatment protocol.
Cost Guide
AED 1,500-3,500/month
Estimated UAE pricing. Costs vary by provider, dosage, and treatment plan.
Frequently Asked Questions
Yes, Tirzepatide (brand name Mounjaro for diabetes, Zepbound for weight management) is available in the UAE through endocrinologists, weight management clinics, and some wellness practices. It requires a prescription. Availability has been impacted by global demand, so wait times may apply.
Most patients notice significant appetite suppression within the first 2-4 weeks. Measurable weight loss typically becomes apparent by 4-8 weeks. Maximum weight loss in clinical trials was achieved at 72 weeks, though most of the effect occurs in the first 36 weeks.
Clinical data shows that approximately two-thirds of lost weight is regained within one year of discontinuation. This is because the medication addresses appetite and metabolic set points that return to baseline without treatment. Many practitioners recommend long-term or maintenance dosing, combined with lifestyle changes, to sustain results.
Tirzepatide is a dual GLP-1/GIP agonist while Semaglutide targets GLP-1 only. Head-to-head trials (SURPASS-2) showed Tirzepatide produced greater HbA1c reduction and weight loss than Semaglutide 1mg. The highest Tirzepatide dose (15mg) showed approximately 5-7% more weight loss than Semaglutide 2.4mg in comparable populations.
Start at the lowest dose and escalate slowly (every 4 weeks minimum). Eat smaller, more frequent meals. Avoid fatty or heavy foods. Ginger tea and anti-nausea medications (ondansetron) can help. Most patients find nausea improves significantly after 4-8 weeks at each dose level.
Where to Get It (UAE)
Browse all wellness centers →Related Treatments
Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Kamura Scores reflect a combination of research evidence, safety, accessibility, and value — they are not clinical recommendations. Research citations are provided for reference; always consult the original publications for complete study details. Consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Individual results may vary.